Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng Kang'ai Fang granules is a Traditional Chinese Medicine (TCM) botanical formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is specifically designed as an adjuvant therapy for patients with advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC), particularly those classified with the TCM "phlegm-dampness" syndrome. The granules are typically administered in combination with immune checkpoint inhibitors, such as PD-1 inhibitors, to enhance therapeutic efficacy in patients with low PD-L1 expression (PD-L1 < 50%). The formulation's mechanism of action is thought to involve the modulation of the host immune system and the gut microbiome to overcome resistance to immunotherapy and improve clinical outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fuzheng kang'ai fang granules.